ClinicalTrials.gg

Program

ceftobiprole medocaril

Also written as “Ceftobiprole medocaril”, “Ceftobiprole medocaril sodium” and “Ceftobiprole Medocaril”.

Its studies are mostly in Community-Acquired Pneumonia · Staphylococcal Skin Infections · Endocarditis, Bacterial · Staphylococcal Infections · Neonatal Sepsis, led by 2 companies.

Furthest: phase 3, since Sep 13, 200511 company-led studies, 1 open or runningNext primary completion: Oct 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Basilea Pharmaceutica100 open or runningphase 3since Sep 13, 2005Sep 13, 2005none ahead
ISTx11 open or runningphase 3since Oct 19, 2026Oct 19, 2026Oct 31, 2028phase 3 · NCT07929493

Also a collaborator on its studies: Innoviva Specialty Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2005First studies: 2 phase 3 studies in Skin Diseases, InfectiousNew to Basilea PharmaceuticaBasilea Pharmaceutica · NCT00210899, NCT00228982
  2. May 12, 2006Phase 3 study in PneumoniaBasilea Pharmaceutica · NCT00326287 · 638 enrolled
  3. Jul 19, 2007Phase 2 study in BacteremiaBasilea Pharmaceutica · NCT00505258
  4. Sep 11, 2007Phase 3 study in FeverBasilea Pharmaceutica · NCT00529282 · 2 enrolled
  5. Aug 5, 2015Phase 1 study in Bacterial InfectionsBasilea Pharmaceutica · NCT02527681 · 15 enrolled · United States, Belgium, Germany and more
  6. Apr 27, 20172 phase 3 studiesBasilea Pharmaceutica · NCT03138733, NCT03137173
  7. Jan 30, 2018Phase 3 study in Community-Acquired PneumoniaBasilea Pharmaceutica · NCT03439124 · 138 enrolled · Bulgaria, Georgia, Hungary and more
  8. Apr 17, 2023Phase 3 study in Neonatal SepsisBasilea Pharmaceutica · NCT05856227 · 9 enrolled · United States, Bulgaria, Estonia and more
  9. Oct 19, 2026ISTx’s first study: phase 3 study in Endocarditis, BacterialNew to ISTxISTx · NCT07929493 · 60 planned

Ahead

  1. Oct 31, 2028Primary completion: phase 3 study in Endocarditis, BacterialISTx · NCT07929493

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Penicillin-binding protein 1 inhibitor; Penicillin-binding protein 2 inhibitor; Penicillin-binding protein inhibitor; Penicillin-binding protein 4 inhibitor”ChEMBL 37, by rule

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07929493Endocarditis, Bacterial3Not yet recruitingISTxOct 31, 202860
NCT05856227Neonatal Sepsis · United States, Bulgaria, Estonia and more3CompletedBasilea PharmaceuticaDec 18, 20249
NCT03439124Community-Acquired Pneumonia · Bulgaria, Georgia, Hungary and more3CompletedBasilea PharmaceuticaMar 16, 2020138
NCT03138733Staphylococcal Infections · United States, Argentina, Bulgaria and more3CompletedBasilea PharmaceuticaMar 11, 2022390
NCT03137173Acute Bacterial Skin and Skin Structure Infections · United States, Bulgaria, Hungary and more3CompletedBasilea PharmaceuticaApr 22, 2019679
NCT02527681Bacterial Infections · United States, Belgium, Germany and more1TerminatedBasilea PharmaceuticaFeb 25, 202015
NCT00529282Fever3TerminatedBasilea PharmaceuticaJan 20082
NCT00505258Bacteremia2WithdrawnBasilea Pharmaceutica0
NCT00326287Pneumonia3CompletedBasilea PharmaceuticaJul 2007638
NCT00228982Skin Diseases, Infectious3CompletedBasilea PharmaceuticaDec 2005784
NCT00210899Skin Diseases, Infectious3CompletedBasilea PharmaceuticaOct 2006828

How it is read

Names in the registry

  • “Ceftobiprole medocaril”, 5 entries
  • “ceftobiprole medocaril”, 4 entries
  • “Ceftobiprole medocaril sodium”, 1 entry
  • “Ceftobiprole Medocaril”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.